Compare OBT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | BCYC |
|---|---|---|
| Founded | 1892 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 360.7M |
| IPO Year | 2021 | 2019 |
| Metric | OBT | BCYC |
|---|---|---|
| Price | $35.06 | $5.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $36.00 | $13.90 |
| AVG Volume (30 Days) | 70.7K | ★ 593.0K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 34.82 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.11 | $4.24 |
| 52 Week High | $37.99 | $9.55 |
| Indicator | OBT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 68.83 | 57.90 |
| Support Level | $29.62 | $5.03 |
| Resistance Level | $37.99 | $5.90 |
| Average True Range (ATR) | 1.10 | 0.25 |
| MACD | 0.32 | 0.09 |
| Stochastic Oscillator | 91.57 | 90.99 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.